MEDI 242-Discovery and design of potent piperidine-based CCR5 antagonists for the potential treatment of HIV-1 infection

被引：0

作者：

Chauder, Brian A. ^{[1
]}

Anderson, Donald ^{[1
]}

Aquino, Christopher J. ^{[1
]}

Bifulco, Neil ^{[1
]}

Boone, Lawrence R. ^{[1
]}

Boros, Eric E. ^{[1
]}

Chong, Pek Y. ^{[1
]}

Du, Kien S. ^{[1
]}

Duan, Maosheng ^{[1
]}

Ferris, Robert G. ^{[1
]}

Kazmierski, Wieslaw M. ^{[1
]}

Kenakin, Terrence P. ^{[1
]}

Koble, Cecilia S. ^{[1
]}

Lang, Daniel G. ^{[1
]}

Peckham, Jennifer P. ^{[1
]}

Spaltenstein, Andrew ^{[1
]}

Thompson, James B. ^{[1
]}

Youngman, Michael K. ^{[1
]}

Wheelan, Patricia J. ^{[1
]}

机构：

[1] GlaxoSmithKline Res & Dev Ltd, Metab & Viral Dis CEDD, Durham, NC 27709 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2006年 / 232卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

242-MEDI

引用

页数：1

共 50 条

[31] Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection
Klibanov, Olga M.
CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (08) : 845 - 859
[32] Synthesis, SAR, and biological evaluation of 4-phenylpiperidine oximes as CCR5 antagonists for the treatment of HIV-1 infection.
Palani, A
Shapiro, S
Clader, JW
Greenlee, WJ
Josien, H
Bara, T
Cox, K
Baroudy, B
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U657 - U657
[33] Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
Latinovic, Olga
Kuruppu, Janaki
Davis, Charles
Le, Nhut
Heredia, Alonso
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1497 - 1510
[34] HIV-1 infection in an individual homozygous for the CCR5 deletion allele
Robyn Biti
Rosemary Ffrench
Judy Young
Bruce Bennetts
Graeme Stewart
Tong Liang
Nature Medicine, 1997, 3 : 252 - 253
[35] HIV-1 infection in an individual homozygous for CCR5 Delta 32
Theodorou, I
Meyer, L
Magierowska, M
Katlama, C
Rouzioux, C
LANCET, 1997, 349 (9060): : 1219 - 1220
[36] HIV-1 infection in an individual homozygous for the CCR5 deletion allele
Biti, R
French, RF
Young, J
Bennetts, B
Stewart, G
Liang, T
NATURE MEDICINE, 1997, 3 (03) : 252 - 253
[37] HIV-1 infection in a man homozygous for CCR5 Delta 32
OBrien, TR
Winkler, C
Dean, M
Nelson, JAE
Carrington, M
Michael, NL
White, GC
LANCET, 1997, 349 (9060): : 1219 - 1219
[38] Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1
Tallant, Matthew D.
Duan, Maosheng
Freeman, George A.
Ferris, Robert G.
Edelstein, Mark P.
Kazmierski, Wieslaw M.
Wheelan, Pat J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1394 - 1398
[39] Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32
Benkirane, M
Jin, DY
Chun, RF
Koup, RA
Jeang, KT
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) : 30603 - 30606
[40] The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies
Dhami, H.
Fritz, C. E.
Gankin, B.
Pak, S. H.
Yi, W.
Seya, M. -J.
Raffa, R. B.
Nagar, S.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2009, 34 (02) : 147 - 160

← 1 2 3 4 5 →